Entresto generic availability 2026?

Short answer: In 2026, there isn’t a widely available generic version of Entresto (sacubitril/valsartan) in the U.S. or many other markets. Generic entry depends on patent status and regulatory exclusivities, so it may not come until after those protections lapse or are resolved in court. If you’re asking about a specific country, the status can be different.

What to do next (country-specific check):
- In the U.S.: You can look up the FDA’s Orange Book to see current patent and exclusivity listings for Entresto. This will show whether a generic sacubitril/valsartan has been approved or is blocked by patents.
- In other countries: Check the local regulatory agency or the national “drug with generic equivalents” database (for example, Health Canada, the European Medicines Agency, or your country’s pharmacy portal) for generic approvals and patent status.

If you want, tell me your country or region and I can look up the latest status and give you country-specific guidance.

Practical notes:
- Generics often reduce cost, but they won’t be available until patents and any related litigation or regulatory exclusivities end.
- Even if a generic sacubitril/valsartan isn’t available yet, some markets may offer generics for the individual components (valsartan or other ARBs) or other heart-failure options. Always consult your clinician about alternatives based on your condition.
- If cost is a concern, talk to your pharmacist or prescriber about patient assistance programs, or whether any approved generic options for the individual components could be appropriate in your case (only under a clinician’s guidance).